Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: Implications for targeted therapeutics

Oncotarget

Volumn 7, Issue 17, 2016, Pages 23454-23467

  Cohen, Philip R ^a   Tomson, Brett N ^b,c   Elkin, Sheryl K ^b,c   Marchlik, Erica ^b,c   Carter, Jennifer L ^b,c   Kurzrock, Razelle ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b N of One   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cancer; Carcinoma; Cell; Cutaneous; Generation; Genomic; Landscape; Merkel; Neuroendocrine; Next; Personalized; Profiling; Sequencing; Targeted; Therapy

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLIN DEPENDENT KINASE INHIBITOR 2C; FANCONI ANEMIA GROUP A PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN MLH1; TUMOR MARKER;

AKT GENE; AKT2 GENE; ARTICLE; ATM GENE; BAP1 GENE; CANCER GENETICS; CDKN2A GENE; CDKN2B GENE; CDKN2C GENE; CELL CYCLE REGULATION; CHEK2 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA REPAIR; FANCA GENE; FBXW7 GENE; GENE IDENTIFICATION; GENE MUTATION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MERKEL CELL TUMOR; MLH1 GENE; NEXT GENERATION SEQUENCING; NF1 GENE; ONCOGENE; PI3K GENE; PIK3CA GENE; PIK3R1 GENE; PTEN GENE; RB1 GENE; RICTOR GENE; TUMOR SUPPRESSOR GENE; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; MERKEL CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; PROCEDURES; SKIN TUMOR;

BIOMARKERS, TUMOR; CARCINOMA, MERKEL CELL; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR TARGETED THERAPY; PRECISION MEDICINE; SKIN NEOPLASMS;

EID: 84966681514     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8032     Document Type: Article

References (95)

1. Hughes MP, Hardee ME, Cornelius LA, Hutchins LF, Becker JC, Gao L. Merkel cell carcinoma: epidemiology, target, and therapy. Curr Dermatol Rep. 2014; 3:46-53.
2. Marek L, Grzanka A, Chmielowska E, Jankowski M, Schwartz RA, Czajkowski R. Merkel cell carcinoma: an illustrative case and review. Postepy Dermatol Alergol. 2014; 31:325-328.
3. Schwartz JL, Wong SL, McLean SA, Hayman JA, Lao CD, Kozlow JH, Malloy KM, Bradford CR, Frohm ML, Fullen DR, Lowe L, Bichakjian CK. NCCN guidelines implementation in the multidisciplinary Merkel cell carcinoma program at the University of Michigan. J Natl Compr Cancer Netw. 2014; 12:434-441.
4. Raju S, Vazirnia A, Totri C, Hata TR. Treatment of Merkel cell carcinoma of the head and neck: a systematic review. Dermatol Surg. 2014; 40:1273-1283.
5. Prewett SL, Ajithkumar T. Merkel cell carcinoma: current management and controversies. Clinica Oncology. 2015; 27:436-444.
6. Munoz IP, Masferrer JP, Vegas JO, Montalvo MSM, Diaz RJ, Casas AMP. Merkel cell carcinoma from 2008 to 2012: reaching a new level of understanding. Cancer Treatment Reviews. 2013; 39:421-429.
7. Nghiem P, Bhatia S, Daud A, Friedlander P, Kluger H, Kohrt H, Kudchadkar R, Lipson E, Lundgren L, Margolin K, Reddy S, Shantha E, Sharfman W, et al. Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma [Abstract 22LBA: 18th ECCO-40th ESMA European Cancer Congress, Vienna, Austria, 25-29 September 2015]. European J Cancer. 2015; 51:S720-S721.
8. Moshiri AS, Nghiem P. Milestones in the staging, classification, and biology of Merkel cell carcinoma. J Natl Compr Canc Netw. 2014; 12:1255-1262.
9. Miller NJ, Bhatia S, Parvathaneni U, Iyer JG, Nghiem P. Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. Curr Treat Options Oncol. 2013; 14:249-263.
10. Aldabagh B, Joo J, Yu SS. Merkel cell carcinoma: current status of targeted and future potential for immunotherapies. Semin Cutan Med Surg. 2014; 33:76-82.
11. Tothill R, Estall V, Rischin D. Merkel cell carcinoma: emerging biology, current approaches, and future directions. Am Soc Clin Oncol Educ Book. 2015; 35:e519-e526.
12. Erstad DJ, Cusack JC Jr. Mutational analysis of Merkel cell carcinoma. Cancers. 2014; 6:2116-2136.
13. Harms PW, Vats P, Verhaegen ME, Robinson DR, Wu YM, Dhanasekaran SM, Palanisamy N, Siddiqui J, Cao X, Su F, Wang R, Xiao H, Kunju LP, et al. The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. Cancer Research. 2015; 75:3720-7.
14. Wong SQ, Waldeck K, Vergara IA, Schröder J, Madore J, Wilmott JS, Colebatch AJ, De Paoli-Iseppi R, Li J, Lupat R, Semple T, Arnau GM ,Fellowes A. UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research. 2015; 75:5228-34.
15. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular Cancer Therapeutics. 2015; 14:847-856.
16. Goh G, Walradt T, Markarov V, Blom A, Riaz N, Doumani R, Stafstrom K, Moshiri A, Yelistratova L, Levinsohn J, Chan TA, Nghiem P, Lifton RP, et al. Mutational landscape of MCPyVpositive and MCPyV-negative merkel cell carcinomas with implications for immunotherapy. 2015; 2015. [Epub ahead of print].
17. Brunner M, Thurnher D Pammer J, Heiduschka G, Petzelbauer P, Schmid C, Schneider S, Erovic BM. Expression of hedgehog signaling molecules in Merkel cell carcinoma. Head Neck. 2010; 32:333-340.
18. Xie H, Liu T, Wang N, Bjornhagen V, Hoog A, Larsson C, Lui WO, Xu D. TERT promoter mutations and gene amplification: promoting mutations and gene amplification: promoting TERT expression in Merkel cell carcinoma. Oncotarget. 2014; 5:10048-10057. doi: 10.18632/oncotarget.2491.
19. Lassacher A, Heitzer E, Kerl H, Wolf P. p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in Merkel cell carcinoma. J Invest Dermatol. 2008; 128:1788-1796.
20. Sihto H, Kukko H, Koljonen V, Sankila R, Bohling T, Joensuu H. Merkel cell polyomavirus infection, large T antigen, retinoblastoma protein and outcome in Merkel cell carcinoma. Clin Cancer Res. 2011; 17:4806-4813.
21. Cimino PJ, Robirds DH, Tripp SR, Pfeifer JD, Abel HJ, Duncavage EJ. Retinoblastoma gene mutations detected by whole exome sequencing of Merkel cell carcinoma. Modern Pathol. 2014; 27:1073-1087.
22. Sahi H, Savola S, Sihto H, Koljonen V, Bohling T, Knuutila S. RB1 gene in Merkel cell carcinoma: hypermethylation in aall tumors and concurrent heterozygous deletions in the polyomavirus-negative subgroup. Acta Pathologica Microbiologica Et Immunologica Scandinavica. 2014; 122:1157-1166.
23. Cohen PR, Kurzrock R. Merkel cell carcinoma with a suppressor of fused (SUFU) mutation: case report and potential therapeutic implications. Dermatol Ther (Heidelb). 2015; 5:129-143.
24. Hafner C, Houben R, Baeurle A, Ritter C, Schrama D, Landthaler M, Becker JC. Activation of the PI3K/AKT pathway in Merkel cell carcinoma. PLoS One. 2012; 7:e31255.
25. Nardi V, Song Y, Santamaria-Barria JA, Cosper AK, Lam Z, Faber AC, Boland GM, Yeap BY, Bergethon K, Scialabba VL, Tsao H, Settleman J, Ryan DP, et al. Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res. 2012; 18:1227-11236.
26. Swick BL, Srikantha R, Messingham KN. Specific analysis of KIT and PDGFR-alpha expression and mutational status in Merkel cell carcinoma. J Cutan Pathol. 2013; 40:623-630.
27. Kartha RV, Sundram UN. Silent mutations in kit and pdgfra and coexpression of receptors with SCF and PDGFA in Merkel cell carcinoma: implications for tyrosine kinasebased tumorigenesis. Mod Pathol. 2008; 21:96-104.
28. Van Gele M, Leonard JH, van Roy N, Cook AL, de Paepe A, Speleman F. Frequent allelic loss at 10q23 but low incidence of pten mutation in Merkel cell carcinoma. Int J Cancer. 2001; 92:409-413.
29. Larramendy ML, Koljonen V, Bohling T, Tukiainen E, Knuutila S. Recurrent DNA copy number changes revealed by comparative genomic hybridization in primary Merkel cell carcinomas. Mod Pathol. 2004; 17:561-567.
30. Xie H, Lee L, Caramuta S, Hoog A, Browaldh N, Bjornhagen V, Larsson C, Lui WO. MicroRNA expression patterns related to Merkel cell polyomavirus infection in human Merkel cell carcinoma. J Invest Dermatol. 2014; 134: 507-517.
31. Loader DE, Feldmann R, Baumgartner M, Breier F, Schrama D, Becker JC, Steiner A. Clinical remission of Merkel cell carcinoma after treatment with imatinib. J Am Acad Dermatol. 2013; 69:e181-e183.
32. National Cancer Institute. A phase II trial of sti-571/imatinib (Gleevec) (Nsc-716051) in neuroendocrine carcinoma of the skin (Merkel cell carcinoma). Available online: http:// clinicaltrials.gov/show/nct00068783 (accessed on 24 October 2015).
33. Davids MS, Charlton A, Ng SS, Chang ML, Laubscher K, Dar M, Hodge J, Soong R, Goh BC. Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma. J Clin Oncol. 2009; 27:e97-e100.
34. Lodish MB, Stratakis CA. Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes. Best Practice & Research Clinical Endocrinology & Metabolism. 2010; 24:439-449.
35. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, et al. RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group: Everolimus for advanced pancrease nonendocrine tumors. N Engl J Med. 2011; 364:514-523.
36. Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, Merghoub T, Ribas A, Chapman PB, et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Research. 2014; 74:2340-2350.
37. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-paul S, Tsimberidou AM, Kurzrock R. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlations between progression-free survival and bevacizumab-containing therapy. Oncotarget. 2013; 4:705-714. doi: 10.18632/oncotarget.974.
38. Schwaederle M, Lazar V, Validire P, Hansson J, Lacroix L, Soria JC, Pawitan Y, Kurzrock R. VEGF-A expression correlates with TP53 mutations in non-small cell lung cancer: implications for antiangiogenesis therapy. Cancer Res. 2015; 75:1187-1190.
39. Sun SY. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Letters. 2013; 340:1-8.
40. Pike KG, Malaqu K, Hummersone MG, Menear KA, Duggan HM, Gomez S, Martin NM, Ruston L, Pass SL, Pass M: Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg Med Chem Letters. 2013; 23:1212-1216.
41. Slotkin EK, Patwardhan PP, Vasudeva SD, de Stanchina E, Tap WD, Schwartz GK. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and softtissue sarcoma. Mol Cancer Ther. 2015; 14:395-406.
42. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A Tsimberiduo AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, LU KH, Kurzrock R. PI3K/ AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012; 30:777-782.
43. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberdou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Reports. 2014; 6:377-387.
44. O'Sullivan, Coyne G, Chen A, Kummar S. Delivery on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy. Curr Opin Oncol. 2015; 27:475-481.
45. Scott CL, Swisher EM, Kaufmann SH. Poly (ADPribose) polymerase inhibitors: recent advances and future development. J Clin Oncol. 2015; 33:1397-1406.
46. Tangutoori S, Baldwin P, Sridhar S. PARP inhibitors: a new era of targeted therapy. Maturitas. 2015; 81:5-9.
47. Steffen JD, Brody JR, Armen RS, Pascal JM. Structural implications for selective targeting of PARPs. Front Oncol. 2013; 3:301.
48. Tutt A, Robinson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376:235-244.
49. Bao Z, Cao C, Geng X, Tian B, Wu Y, Zhang C, Chen Z, Li W, Shen H, Ying S. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: a systematic review and meta-analysis. Oncotarget. 2015; doi: 10.18632/oncotarget.5367. [Epub ahead of print].
50. Angevin E, Lopez-Martin JA, Linn CC, Gschwend JE, Harzstark A, Castellano D, Soria JC, Sen P, Chang J, Shi M, Kay A, Escudier B. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res. 2013; 19:1257-1268.
51. Corrado A, Ferrari SM, Politti U, Mazzi V, Miccoli M, Materazzi G, Antonelli A, Ulisse S, Fallahi P, Miccoli P. Aggressive thyroid cancer: targeted therapy with sorafenib. Minerva Endocrinol. 2015; Jun 26. [Epub ahead of print].
52. Taipale M, Krykbaeva I, Whitesell L, Santagata S, Zhang J, Liu Q, Gray NS, Lindquist S. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat Biotechnol. 2013; 31: 630-637.
53. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014; 371:1005-1015.
54. Ewald F, Grabinski N, Grottke A, Windhorst S, Norz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jucker M. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer. 2013; 133:2065-2076.
55. Dumble M, Crouthamel MC, Zhang SY, Schaber M, Levy D, Robell K, Liu Q, Figueroa DJ, Minthorn EA, Seefeld MA, Rouse MB, Rabindran SK, Heerding DA, et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with MEK inhibitor. PLoS One. 2014; 9:e100880.
56. Rocca A, Farolfi A, Bravaccini S, Schirone A, Amadori D. Palbociclib [PD 0332991]: targeting the cell cycle machinery in breast cancer. Expert Opin Pharmacol. 2014; 15:407-420.
57. Wheler JJ, Tsimberdou AM,Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Molecular Cancer Therapeutics. 2013; 12:2167-2175.
58. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006; 66:8109-8115.
59. Howard SMj, Yanez DA, Stark JM. DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining. PLoS Genetics. 2015; 11:e1004943.
60. Tentori L, Leonetti C, Muzi A, Dorio AS, Porru M, Dolci S, Campolo F, Vernole P, Lacal PM, Praz F, Graziani G. Influence of MLH1 on colon cancer sensitivity to poly(ADPribose) polymerase inhibitor combined with irinotecan. Int J Oncol. 2013; 43:210-218.
61. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015; 372: 2509-2520.
62. Koo J, Yue P, Deng X, Khuri FR, Sun SY. mTOR complex 2 stabilizes Mcl-a protein by suppressing its glycogen synthase kinase 3-dependent and SCF-FBXW7-mediated degradation. Mol Cell Biol. 2015; 35:2344-2355.
63. Li S, Oh YT, Yue P, Khuri FR, Sun SY. Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells. Oncogene. 2015; Apr 20. [Epub ahead of print].
64. Messersmith WA, Shapiro GI, Clearh JM, Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, McLachlan KR, Kern KA, et al. A phase I, dose-finding study in patients with advanced solid malignancies of the oral gamma-secretase inhibitor PF-0308401. Clin Cancer Res. 2015; 21:60-67.
65. Dantas-Barbosa C, Bergthold G, Daudigeos-Dubus E, Blackus H, Boylan JF, Ferreira C, Puget S, Abely M, Vassal G, Grill J, Geoerger B. Inhibition of the NOTCH pathway using gamma-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors. Anticancer Drugs. 2015; 26:272-283.
66. Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PA, Taylor AM, Stankovic T. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood. 2010; 116:4578-4587.
67. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368:2385-2394.
68. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, et al. Activity of XL184 (Cobazantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011; 29:2660-2666.
69. Euhus D. Genetic testing today. Ann Surg Oncol. 2014; 21:3209-3215.
70. VonHoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, et al. Inhibition of the hedgehog pathway in advanced basal cell carcinoma. N Engl J Med. 2009; 361:1164-1172.
71. Femia AP, Soares PV, Luceri C, Lodovici M, Giannini A, Caderni G. Sulindac, 3, 3'-diindolylmethane and curcumin reduce carcinogenesis in the Pirc rat, an Apc-driven model of colon carcinogenesis. BMC Cancer. 2015; 15:611.
72. Bi X, Pohl N, Dong H, Yang W. Selenium and sulindac are synergistic to inhibit intestinal tumorigenesis in Apc/p21 mice. J Hematol Oncol. 2013; 6:8.
73. Andea AA, Patel R, Ponnazhagan S, Isayeva T, Kumar S, Siegal GP. Detection of Merkel cell polyomavirus in formalin-fixed, paraffin-embedded tissue of Merkel cell carcinoma and correlation with prognosis. Rom J Morphol Embryol. 2014; 55:1057-1062.
74. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008; 73:1849-1850.
75. Van Gele M, Kaghad M, Leonard JH, Van Roy N, Naeyaert JM, Geerts ML, Van Belle S, Cocquyt V, Bridge J, Solot R, De Wolf-Peeters C, De Paepe A, Caput D, et al. Mutation analysis of P73 and TP53 in Merkel cell carcinoma. Br J Cancer. 2000; 82:823-826.
76. Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang LC, Penas PF, Nghiem P. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol. 2008; 58:375-381.
77. Lill C, Schneider S, Item CB, Loewe R, Houben R, Halbauer D, Heiduschka G, Brunner M, Thurnher D. P53 mutation is a rare event in Merkel cell carcinoma of the head and neck. Eur Arch Otorhinolaryngol. 2011; 268: 1639-1646.
78. Houben R, Dreher C, Angermeyer S, Borst A, Utikal J, Haferkamp S, Peitsch WK, Schrama D, Hesbacher S. Mechanisms of p53 restriction in Merkel cell carcinoma cells are independent of the Merkel cell polyoma virus T antigens. J Invest Dermatol. 2013; 133:2453-2460.
79. Papadaki H, Finkelstein SD, Kounelis S, Bakker A, Swalsky PA, Kapadia SB. The role of p53 mutation and protein expression in primary and recurrent adenoid cystic carcinoma. Hum Pathol. 1996; 27:567-572.
80. Wie W, Wang Y, Yu X, Ye L, Jinag Y, Cheng Y. Expression of TP53, BCL-2, and VEGFA genes in esophagus carcinoma and its biological significance. Med Sci Monit. 2015; 21:3016-3022.
81. Ghiasi N, Habibagahi M, Rosli R, Ghaderi A, Yusoff K, Hosseine A, Abdullah S, Jaberipour M. Tumor suppressive effects of WEE1 gene silencing in breast cancer cells. Asian Pac J Cancer Prev. 2014; 14:6605-6611.
82. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
83. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nature Reviews Cancer. 2009; 9:153-166.
84. Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shima K, Parker BA, Fanta P, Kurzrock R. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. Cell Cycle. 2015; 14:1252-1259.
85. Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Cyclin alterations in diverse cancers: outcome and coamplification network. Oncotarget. 2015; 6:3033-3042. doi: 10.18632/oncotarget.2848.
86. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006; 24:1770-1783.
87. Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clinical Cancer Research. 2013; 19:5320-5328.
88. Veija T, Sarhadi VK, Koljonen V, Bohling T, Knuutila S. Hotspot mutations in polyomavirus positive and negative Merkel cell carcinomas. Cancer Genetics. 2015; S2210-776200234-3.
89. Pipas JM, Levine AJ. Role of T antigen interactions with p53 in tumorigenesis. Semin Cancer Biol. 2001; 11:23-30.
90. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced tumors. PloS One. 2011; 6:e22769.
91. Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. A framework for genomic biomarker actionabiity and its use in clinical decision making. Oncoscience. 2014; 1:614-623.
92. Kurzrock R, Giles FJ. Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes. Cell Cycle. 2015; 14:2219-2221.
93. Wheler J, Lee JJ, Kurzrock R. Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. Cancer Res. 2014; 74:7181-7184.
94. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, et al. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget. 2014; 5:2349-2354. doi: 10.18632/oncotarget.1946.
95. Harms PW, Collie AMBC, Hovelson DH, Cani AK, Verhaegen ME, Patel RM, Fullen DR, Omata K, Dlugosz AA, Tomlins SA, Billings SD. Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation. Mod Pathol. 2016; doi: 10.1038/ modpathol.2015.154.